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We have raised CD8 § cytotoxic T lymphocytes (CTL) from three Epstein-Barr virus-seroposi- 
tive donors by incubating peripheral blood lymphocytes with irradiated autologous B95.8-strain 
EBV-transformed B lymphoblastoid cells  (LCL).  However, to detect lysis in a standard SlCr 
release assay of the LCL against which these CTL were raised, superinfection with recombinant 
vaccinia expressing the appropriate EBV protein or incubation with the peptide epitope was necessary. 
The untreated LCL were not lysed, even though Western blotting demonstrated that they expressed 
the EBV antigens containing the CTL epitopes. We have found CTL of this phenotype that 
are restricted by human leukocyte antigen-A2, -A3, -B7,  or -B39,  and which recognize the 
EBV latent proteins, EBV nuclear antigen (EBNA)-3A, EBNA-3C, or terminal protein. During 
these experiments, we identified a new human leukocyte antigen-A3-restricted EBNA-3A epitope, 
residues 603-611,  RLtLAEAGVK. We raised a spontaneous LCL, transformed by endogenous 
EBV, from one donor, but this was also not lysed. For at least one of the epitopes, CTL from 
another donor lysed the LCL without superinfection or addition of peptides. We conclude that 
the CTL were unable to achieve a high enough avidity of interaction with untreated LCL to 
trigger effector function, although the LCL were able to stimulate them to grow in vitro for 
up to 4 too. To assess whether a small percentage of the LCL might possess  a higher antigen 
density, we used an assay of tumor necrosis factor release from a CTL clone, which was able 
to detect antigen-bearing cells representing only 1% of a stimulating LCL population. Nevertheless, 
the untreated autologous LCL line failed to stimulate tumor necrosis factor release. 
E 
BV is a gamma herpes virus of humans that productively 
infects epithelial cells, principally in the oropharynx, and 
establishes latency in B cells (1). Infection usually occurs asymp- 
tomatically in childhood or adolescence, but in some indi- 
viduals a vigorous proliferative cellular immune response results 
in the clinical syndrome of infectious mononucleosis (IM) a 
(2). Thereafter, the immune response controls but does not 
eradicate the virus;  virus  continues  to  be  shed from  the 
oropharynx, probably for life, and latently infected B lym- 
phocytes persist throughout life. Two main types of latent 
1 Abbreviations used in  this paper: EBNA, EBV nuclear antigen; IM, 
infectious mononucleosis;  LCL, lymphoblastoid  cell lines; LD, limiting 
dilution; LT, Lymphocult  T; rVV, recombinant  vaccinia virus; SA, soft 
agar; XLP, X-linked lymphoproliferative  syndrome. 
infection of B lymphocytes are recognized (3).  In the first, 
only the latent protein EBV nuclear antigen (EBNA)-I  is 
expressed and is responsible for maintenance of the EBV epi- 
somes in infected cells. In the second, there is expression of 
all the latent proteins (EBNA-1, -2, -3A, -3B, -3C, -LP, and 
-LMP1 and 2); these cells proliferate indefinitely in vitro as 
lymphoblastoid cell lines (LCL), and polyclonal proliferations 
of EBV-infected B cells with the same pattern of gene ex- 
pression can occur in vivo in immunosuppressed individuals 
(2,  3).  Most infectious virus production in vivo occurs in 
the oropharyngeal epithelium, and it is from this site that 
infection of new hosts is established (2, 3). The oropharyn- 
geal epithelium may be periodically reseeded by circulating 
latently infected B cells. 
The main immune cell responsible for control of EBV in 
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be found in infected individuals in high frequency throughout 
life, implying a high level of continued virus activity. CTL 
recognizing each of the EBV latent proteins except EBNA-1 
have been identified (5-8) and are thought to perform an im- 
munosurveillance function, destroying immortalized EBV- 
infected B cells. Thus, in the infected individual, CTL appear 
to be directed against cells that are the in vivo equivalent 
of LCL (9). 
These CTL can be reactivated in vitro by exposure to LCL. 
The protocol usually adopted involves culturing PBL from 
infected individuals in the presence of small numbers of ir- 
radiated autologous LCL (5-8). CTL are maintained in vitro 
for extended periods by restimulation with irradiated autol- 
ogous LCL in the presence  of lymphokines. CTL lines  so 
generated are usually screened for EBV specificity by their 
ability to lyse LCL in an EBV-specific, HLA class I-restricted 
manner. The target antigen recognized can then be identified 
by lysis of EBV-negative HLA-matched cells infected with 
recombinant vaccinia virus (rVV) expressing the relevant EBV 
latent genes. However, this protocol often produces lines or 
clones that either fail to lyse autologous LCL or for which 
no clear  HLA+  virus specificity can be assigned. 
Here we report that we have used the standard protocol 
to induce CTL in vitro, but we extended the screening pro- 
cedure by testing all clones for lysis of rVV-infected targets 
regardless of whether or not they lysed LCL. In three indi- 
viduals, we found that most of the CTL clones we generated 
showed classic patterns of class I restriction and specificity 
for EBV latent proteins but failed to lyse the LCL that were 
used to activate  them in vitro. 
Materials and Methods 
Establishment and Maintenance of EBVtrans.formed Cell Lines. 
B95.8-strain EBV-transformed  B-LCL  were established  by culturing 
PBL with supernatant from the marmoset line B95.8 m the pres- 
ence of I pg/ml cyclosporin  A. The endogenous-strain  EBV-trans- 
formed LCL  ]'B-spont was obtained  by spontaneous outgrowth from 
JB PBL cocultured with cord blood lymphocytes in the presence 
of cyclosporin A. The origin of the line JB-spont was confirmed 
as JB rather than the allogeneic  cord blood by isoelectric focusing 
of class I HLA. 
CTL Lines and Clones.  EBV-specific  CTL lines were established 
as previously  described (8). Briefly,  PBL (3  x  107) from the EBV- 
seropositive  donor  JB were cultured with irradiated (2,000 tad) au- 
tologous B95.8-transformed LCL (3  x  10s). For polyclonal  lines, 
the cultures were restimulated with autologous LCL at a stimu- 
lator to responder ratio of 1:4 on day 11, and 20% supernatant 
of the T cell line MLA (MLASN) was added as a source of IL-2 
on day 14. Thereafter, the lines were restimulated with autologous 
LCL weekly and maintained in 20%  MLASN. Soft agar (SA) 
oligoclonal  lines were established from PBL 3 d after initial stimu- 
lation as described (6), and they were maintained long term by 
weekly  restimulation  with irradiated  autologous  B95.8-transformed 
LCL and cultured in RPMI 1640 supplemented  with 20 U/ml rlL-2 
(Cetus Corp., Emeryville,  CA) and 10% Lymphocult T (LT; Bio- 
test, UK), or 20% MLASN. Limiting dilution (LD) oligoclonal 
lines and subclones were obtained by culturing CTL from estab- 
lished lines in 96-well plates at 0.3/well in the presence of pooled 
irradiated (3,000 tad) PBL from three donors (103/ml), autologous 
LCL (10S/ml), and 0.5 gg/ml PHA  (WeUcome Reagent Ltd., 
Beckenham, UK) ("cloning mix") in a volume of 100 gl. 3 d later, 
100/zl of 20% LT was added to each well. After 11 d, growing 
colonies were transferred to 24-well plates (Costar Corp., High 
Wycombe, UK) in the presence of 1 ml doning mix, a further 
1 ml of 20% LT was added 3 d later, and the clones/lines were 
maintained thereafter in 10% LT with weekly restimuhtion with 
autologous LCL. Sometimes clones were maintained in 20 U/ml 
rIL-2 in addition to LT. 
Peptide.  Peptides were synthesized using Fmoc chemistry and 
analyzed by HPLC.  The EBNA-3A peptide RPPlFIRRL was 
>95% pure. The biochemical analysis of the EBNA 3C peptides 
QPRAPIRPI and QPRAPIRPltrF is complicated by cyclization 
of  the amino-terminal  glutamine to pyroglutamate, which recurred 
after HPLC purification. The concentrations quoted here repre- 
sent the major HPLC peak, corresponding to the native species. 
QPRAPIRPI is less well recognized  in CTL assays  than QPRAPIR- 
PIPT (10). 
rVV.  rVV expressing the  EBV latent genes EBNA-3A and 
EBNA-3C, the kind gift of  Dr. E. Kieff (Harvard Medical School, 
Boston, MA), have been previously described (6, 8). 
CTL Assay.  LCL were incubated with peptide (10 -6 M) or 
NV (10 PFU per cell) overnight, and then labeled for 1 h with 
100 mCi SlCr, washed three times, and added at 5 x  103 cells per 
well to round-bottomed 96-well plates with or without CTL as 
indicated. Maximum 51Cr release was determined by lysis with 
2.5% Triton X-100. After 4 h, 20 gl supernatant was harvested 
and counted on a beta plate counter. Percent specific  lysis was cal- 
culated as 100x (cpm  experimental -  cpm medium)/(cpm Triton 
X-100  -  cpm medium). 
DetectionofEBNA-3AandEBNA-3C.  Expression  of  EBNA-3A 
and EBNA-3C in LCL was assayed by Western blotting using 
ai~nity-purified human  antibodies as described previously (11). 
Briefly, one million cells were solubilized in gel sample buffer and 
were separated  by discontinuous SDS-PAGE using a resolving gel 
containing 7.5%  acrylamide and 0.2%  bisacrylamide (12). The 
resolved proteins were transferred to nitrocellulose by electroblot- 
ring, and the filters  were then blocked by incubating first with 50 
dried skim milk in PBS and then with PBS containing 0.1% Tween 
80 detergent. The viral  proteins were detected  by incubating  replicate 
filters with purified human antibodies to EBNA-3A or EBNA-3C 
followed by nSI-labeled  protein A. The filters were then subjected 
to autoradiography to visualize specifically  bound antibodies. 
TNF Release Assay.  Where indicated, for use as stimulators, 
JB B95.8-transformed LCL were incubated overnight with rVV 
(multiplicity of  infection of 10) or peptide. They were then washed 
three times before adding to CTL. CTL, 10Vwell, were incubated 
in 96-well round-bottomed plates with stimulators at the indicated 
ratios for 14 h, after which the plates were spun and supernatant 
was harvested and stored at  -70~  for later assay of TNF. 
TNF concentration was measured  in 50 #1 of supernatant using 
an ELISA. ELISA plates (Immulon-Dynatech Ltd., Billinghurst, 
UK) were coated with anti-human TNF-c~ monoclonal CB006 
(Celltech, Stough, UK) in 0.2 M N,N-bis(2-hydroxyethyl)-2-amino 
sulphonic acid, pH 7 (BES) (Sigma  Chemical Co., Poole, UK) over- 
night, and then washed three times with 1% BSA in 0.2 M BES. 
50/zl samples or TNF controls were added per well for 1 h at room 
temperature (RT) and removed,  and 50 ~1 rabbit anti-TNF  (Celltech) 
preincubated for 10-60 min at RT in sample diluent (1% BSA, 
2% normal mouse serum in PBS) was added for 1 h at RT. The 
plates were aspirated again, and 50 gl peroxidase-conjugated  donkey 
anti-rabbit IgG (Jackson ImmunoResearch  Laboratories, Inc., West 
2222  Epstein-Barr  Virus-specific Cytotoxic  T Lymphocytes Grove, PA), 1 mg/ml in sample  diluent, preincubated  at RT for 
10-60 min, was added to each well for 30 rain at RT. The plates 
were washed four times with PBS. 100 #1 substrate (0.01 mg/ml 
TMB, 0.01% hydrogen  peroxide  in 0.1 M Na acetate,  pH 5.2; TMB 
was prepared from 1 mg/ml stock in DMSO, and the TMB/Na 
acetate  was filtered  before  addition  of  hydrogen  peroxide)  was added 
per well for 30 min, and the reaction was stopped with  2 M 
HzSO4. Plates were read at 450 nm (reference:  63 nm) within 10 
min. 
Results 
Polyclonal  and Cloned CTL Specific  for EBV Latent Antigens 
Fail to Lyse EBV-transformed  LCL.  A polyclonal CTL line 
from a healthy adult donor, P.G. (HLA-A2, -A3, -B7, -B51), 
raised by stimulating PBL with irradiated autologous LCL, 
showed no lysis of autologous LCL. However, when superin- 
fected with rVV expressing EBNA-3A or EBNA-3C, the au- 
tologous LCL were lysed efficiently (Fig. 1 A). A clone es- 
tablished by LD cloning from this line also failed to lyse 
autologous LCL, but use of rVV demonstrated that it recog- 
nized EBNA-3A restricted through HLA-A3 (Fig. 1 B). Using 
a panel of synthetic peptides covering the entire EBNA-3A 
sequence followed by prediction of the minimal epitope based 
on the published motif for HLA-A3-binding peptides (13), 
the epitope was identified as residues 603-611-RLRAEQVK 
(Fig. 1 C). The clone lysed autologous LCL incubated with 
this peptide. Further clones from a second bleed of P.G. were 
established by cloning in SA. Screening of these revealed  eight 
clones with little recognition of the autologous LCL that 
were specific for EBV terminal protein (TP or LMP2),  re- 
stricted by HLA-A2. Three examples are shown in Fig. 1 D. 
EBV-specific CTL from Two Other Donors Also Fail to Lyse 
Autologous I_CL.  Five  EBV-specific  CTL clones from a second 
donor, J.B. (HLA-A3, -A29, -B7, -B51), which were obtained 
by cloning in SA or by LD using standard techniques, were 
investigated  extensively;  the clones had been kept in continuous 
culture for up to 4 mo by weekly restimulation with irradi- 
ated autologous LCL and lymphokine supplements. All were 
CD8 positive (data not shown), were restricted by HLA-B7, 
and were specific for EBNA-3A 379-387 (RPPIFIRRL) or 
EBNA-3C 881-9 (QPRAPIRPI) (10). Each  clone showed little 
or no lysis of the LCL with which it was stimulated, unless 
the LCL had been exposed to the appropriate peptide or rVV 
(Fig. 2, A-E). Finally, clones from a third donor, A.B. (HLA- 
A2, -A3, -B39, -B51), whose polyclonal CTL line showed 
no clear preference  for autologous LCL, were also tested using 
rVV. These clones also failed to lyse autologous LCL but were 
specific for either EBNA-3A or EBNA-3C, restricted through 
HLA-B39  (Fig. 2 F). 
Neither Poor Expression of EBNA-3A and EBNA-3C Nor 
Strain Variation between B95-8 and Endogenous EBV Account 
for the Failure to Lyse LCL.  We addressed the possibility that 
EBNA-3A and EBNA-3C were poorly expressed in the LCL 
that failed to be lysed. A Western blot of autologous  LCL 
from  the three CTL  donors demonstrated expression  of 
EBNA-3A and EBNA-3C (Fig. 3). Clinical isolates of EBV 
usually have EBNA proteins that differ in sequence from that 
of the prototype laboratory B95.8 strain (14), and the differ- 
ences can affect CTL recognition (15). To exclude the possi- 
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bility that the JB CTL were specific for an epitope in J.B's 
endogenous EBV that cross-reacted only weakly with the 
B95.8 strain, a spontaneous LCL, transformed with the en- 
dogenous EBV strain, was established. As is usual for din- 
ical isolates, this line 0B-spont) showed EBNA of different 
molecular weights than the laboratory B95.8 strain (Fig. 3). 
However, Fig. 4 shows that JB-spont was not lysed by either 
EBNA-3A or EBNA-3C-specific CTL, although it could be 
lysed in the presence of the appropriate  peptide or recom- 
binant vaccinia. The same result was seen with clones  JBLDN 
(EBNA-3C specific)  and JBLD1.4 and JBSA58.1 (EBNA-3A 
specific) (data not shown). 
The Same Epitope Is Recognized by CTL That Lyse Autolo- 
gous LCL and by CTL That Fail  to Lyse Autologous LCL.  We 
had previously identified  a donor whose CTL recognized 
EBNA-3C, restricted by HLA-B7,  which lysed autologous 
and other HLA-B7-positive LCL without addition of pep- 
tide or rVV (Fig. 5 A). A polyclonal CTL line that had been 
established from this donor was screened on overlapping 15- 
met peptides covering the entire EBNA-3C sequence and it 
was found to recognize two overlapping 15 met that con- 
tained the epitope 881-891 (data not shown). This specificity 
was confirmed by lysis of HLA-B7-positive PHA blasts in- 
cubated with peptide EBNA-3C 881-891 (Fig. 5 B). No fur- 
ther studies could be performed with these cells, but this assay 
demonstrated that the same epitope could be recognized by 
CTL from two donors,  one with the ability to lyse LCL, 
the other unable to lyse LCL without additional  antigen. 
Therefore, nonrecognition of LCL is not a property of the 
epitope involved. 
A  TNF Release Assay That Can Detect 1% of  LCL Bearing 
the Appropriate Antigen Is Not Stimulated by Untreated LCL. 
We were puzzled by the ability of the LCL to stimulate CTL 
activation and proliferation without being susceptible to lysis 
by the same CTL clone. We hypothesized that a fraction of 
the cell line, too small to be detected in the killing assay, 
might express adequate amounts of antigen to stimulate CTL. 
To assess this possibility, we studied antigen-specific TNF 
release by the clone LD1.4.  The results are shown in Fig. 
6. Uninfected  JB-B95.8 LCL, JB LCL infected with irrele- 
vant vaccinia,  and the mismatched LCL basilio caused no TNF 
release up to a stimulator (target) to responder (CTL) ratio 
of 10:1. JB LCL infected  with W-EBNA-3A stimulated TNF 
release that was detectable at a stimulator:responder  (S:R) 
ratio  of <0.1.  Even when VV-EBNA-3A-infected  JB cells 
were mixed with varying numbers of the nonstimulatory 
basilio LCL cells so that the total LCL/CTL ratio remained 
fixed at 10:1, a VV-EBNA-3A-infected JB/CTL ratio of 0.1 
still caused TNF release. Thus, in this assay, the CTL could 
detect antigen expressed at the density given by W-EBNA- 
3A infection when present in <1% of the stimulating LCL 
population. Comparison with TNF release  stimulated by LCL 
incubated with peptide from 10-s M to 10-10 M (Fig. 6 B) 
indicated that the density of antigen achieved  by VV-EBNA- 
3A infection was equivalent to that achieved by overnight 
incubation with "~10  -s-5 M peptide. We conclude that <1% 
of the untreated LCL population can express the peptide epi- 
tope at this density. A  60T 
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Figure  1.  Polyclonal and cloned EBV-specific CTL from donor P.G. were able to lyse the autologous LCL only if they were infected with rVV 
expressing the appropriate EBV protein or incubated with peptide. (A) CTL assay of polyclonal CTL line from donor P.G. (HLA-A2, -A3, -BT, -B51) 
tested against autologous B95.8 LCL infected with irrelevant VV (thymidine kinase negative) or rW expressing the EBV latent proteins indicated. 
(B) A CTL clone (PG1) failed to lyse uninfected autologous LCL but lysed autologous I.CL or LCL matched only at HLA-A3 (NW:HLA-A3, -Aw33, 
-BS, -B2702) superinfected with  VV-EBNA-3A. (C) Lysis by the clone PGI  of autologous LCL incubated with  the peptide EBNA-3A 603-611 
(RLRAEAQVK), E/T 5:1. (D) A second series of clones raised in SA from P.G. recognized autologous LCL only if superinfected with vv:rP; lysis 
of the transfectant C1R-A2 (HLA-A2, -Cw4) infected with VV-TP identified HLA-A2 as the restriction element. 
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Figure  2.  EBV-specific  CTL from two other donors 
recognizing four other epitopes also failed to lyse autolo- 
gous I.CL. (A-E) Five clones raised from the donor J.B. 
by LD or by cloning in SA were specific for EBNA-3A 
379-387  (RPP1FIRRL) (A-C) or  EBNA-3C 881-9 
(QPRAPIRPI) (D and E), restricted through HLA-B7. 
Each required either superinfection with rW or incuba- 
tion with the peptide epitope to lyse autnlugous  I.CL 0B- 
B95.8). (F) Clones derived by SA cloning from a third 
donor, A.B. (A2, A3, B39, B51), failed to lyse untreated 
autolognus LCL but  lysed autologous IX2L or  LCL 
matched only at HLA-B39 (8MH) infected with  VV- 
EBNA-3A (clones AB2 and AB9) or W-EBNA-3C (clones 
AB5 and AB8). 
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transformed and spontaneous LCL used in this study  Western blot of 
EBNA-3A and EBNA-3C in the autologous LCL used in this study that 
were not lysed by EBV-specific  CTL shows normal levels of EBNA expres- 
sion. The different molecular weight of EBNA-3A and -3C in the sponta- 
neously arising LCL JB-spont confirm the endogenous origin of the virus 
responsible for transformation of this line. 
JB EBNA-3A-specific  Clones Show a Prominent  Allo Cross- 
reactivity.  Alloreactivity without apparent EBV specificity 
is a prominent feature of the CTL response  to EBV and a 
striking feature of the CTL found in infectious mononucle- 
osis  (16,  17).  In Fig. 7,  an assay with JBLD1.4  shows lysis 
of three  unrelated  allo  targets.  The other EBNA-3A  379- 
387-specific clones from J.B. displayed the same pattern of 
alloreactivity  (data  not  shown).  Ahhough a family study 
showed that  the allospecificity  was clearly  encoded in the 
MHC, the antigen recognized has not been identified (data 
not shown). These results indicate that the common finding 
of alloreactivity  without apparent EBV specificity  in CLT- 
stimulated EBV may after all be due to classical class I-re- 
stricted EBV-specific  CTL; however,  the EBV specificity  of 
the CTL may remain cryptic  unless the antigen density is 
raised by superinfection  with appropriate rVV or by exoge- 
nous peptide. 
Discussion 
We have found in three EBV-seropositive individuals CTL 
that fail to lyse the autologous CTL against which they were 
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(A) unless  incubated with  the  peptide QPRAPIRPIPT,  or by the EBNA-3A-specific  clone JB0.3C  (B) unless  infected  with VV-EBNA-3A. 
i  60 
50 
40 
~  3o 
20 
10 
~ 
0 
10:1 
E:T 
￿9  autologous 
(A3,24 B7) 
--o---  I.B. 
(A2,B7) 
--~  K.S. 
(A2,11 ,B3 
￿9  5,40) 
5:1  -----o---- L.C. (All, 
B7,18) 
80 
60 
"q  40 
20 
0  ￿9 
20:1  10:1 
E:T 
--=-~-  + DMSO 
QR:W:~RRPT 
Figure  5.  CTL from another donor that are able to lyse LCL also recognize EBNA-3C 881-891. A polyclonal line from the donor C.F. lysed autolo- 
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of the epitope EBNA-3C 881-889. 
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Figure  6.  A TNF release assay  can detect 1% of LCL bearing the ap- 
propriate antigen  but is not stimulated  by untreated LCL. TNF release 
by the clone  JBLD1.4 (EBNA-3A specific) was used as an indicator of 
antigen-specific CTL-target (stimulator) interaction. (A) 10  s JBLD1.4 
CTL per well were incubated with mismatched  LCL (basilio: HLA-A2, 
-B51), JB-B95.8 LCL, or JB-B95.8 LCL infected  with irrelevant  vaccinia 
(VV-TP), or VV-TP at stimulator  (target)/CTL  ratios  indicated.  The con- 
centration of TNF release by the CTL was measured  by ELISA  and OD, 
proportional  to TNF concentration,  plotted  against  target/CTL  ratio. Only 
LCL infected  with W-EBNA-3A  caused  TNF release  at target/CTL  ratios 
of up to 10:1. Basilio LCL were mixed with JB LCL infected  with VV- 
EBNA-3A such that the total target CIB-VV-EBNA-3A + basilio)/CTL 
ratio was 10:1. The ratio plotted is that of JB-VV-EBNA-3A/CTL  (MIX 
10:1). This indicated  that JB-VV-EBNA-3A caused specific  TNF release 
even when it was present as only 1% of the target population. (/3) JB 
LCL were incubated  with peptide P,  PPIFIRRL overnight at concentra- 
tions from I0-LI0  - 10, washed  three times, and used in the assay  as above. 
Comparison of the curves in A and B indicates that infection  with VV- 
EBNA-3A caused equivalent  TNF release to that achieved  by incubation 
overnight with '~10  -s.s M peptide. 
raised and repeatedly restimulated for long-term culture. These 
CTL display clear class I restriction and EBV specificity, and 
in one case we have shown that the specificity recognized 
is the same as that of "classic" EBV-specific CTL from an- 
other donor that are able to lyse the LCL. One previous ex- 
ample of CTL raised against an endogenous LCL that was 
unable to lyse the B95.8 strain-transformed LCL was shown 
to be caused by sequence difference in the epitope between 
B95.8  and the endogenous virus (15, 18). We have shown 
that this is not the explanation for our findings, as the LCL 
generated by transformation with J.B.'s endogenous virus were 
also not lysed by the JB clones specific for two different epi- 
topes.  This finding is also not due to intrinsic resistance  to 
lysis by the LCL, as they were easily lysed when antigen con- 
centration was increased by addition of peptide or recom- 
80  T 
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Figure 7.  JBLD1.4  lyses mismatched  LCL because of a cross-reactive 
allospecificity.  JB LD1.4  was tested  for lysis  against  a panel of  I,  CL: autol- 
ogous 0B), GM7032 (HLA-A1,  -BS, -B52), DukMN (HLA-A2,  -Aw33, 
-B51, -B53), GM6988 (HLA-A2,  -B13, -B51), JM (HLA-A2,  -B15, -B51), 
GM7015 (A1, A39, B52, ]360). Lysis  of  the HLA-B7-negative  LCL  GM6988, 
JM, and GM7015 demonstrates  that  JBLD1.4 recognizes a cross-reactive 
allospecificity. 
binant vaccinia. For the same reason, the phenomenon cannot 
be attributed to poor lytic ability of the CTL, nor was there 
an absolute absence of antigen in the LCL, as expression  of 
both EBNA-3A and -3C was detected by Western blot. Simi- 
larly, the level of the adhesion molecules ICAM-1, ICAM-3, 
and LFA-1 was typically high on the unlysed LCL and was 
not increased by infection with rVV (data not shown). We 
conclude that the avidity of interaction between native LCL 
and these CTL was inadequate to reach the threshold required 
to trigger effector function in the CTL. Alteration of either 
side of the avidity equation could lead to lysis. Increasing 
the antigen density on the LCL with peptide or rVV led to 
target lysis by the JB clones. Alternately, the untreated LCL 
could be lysed by CTL from another donor whose CTL dis- 
played a higher avidity, presumably achieved either by a higher 
affinity TCR or by a higher level of TCK expression.  High 
avidity CTL could not be generated from jB PBL even with 
an efficient peptide restimulation protocol; although this pro- 
tocol effciently  restimulated CTL that were able to lyse targets 
treated with the appropriate peptide, they were nevertheless 
unable to lyse untreated LCL (data  not shown). 
The finding of CTL that have been raised against untreated 
LCL but are unable to lyse them is unexpected because it 
is in contrast to the general assumption made by immunolo- 
gists that the antigen density required to trigger T cell acti- 
vation should be higher than that required to trigger T cell 
effector functions, such as cytolysis and lymphokine release. 
We therefore postulated that a small percentage of the LCL 
may at any given time express a high enough density of an- 
tigen to trigger CTL activation and proliferation, Because 
a killing assay is insensitive if <10-20% of the cells express 
the antigen, we developed a cytokine release assay that was 
able to detect TNF release from the CTL clone when 1% 
of the stimulating LCL displayed the correct antigen (in the 
form of rVV).  We found that the LCL did not cause TNF 
release in this assay unless they had been exposed to peptide 
or rVV. Increasing peptide concentration caused progressively 
more TNF release, evidenced by a shift to the right in the 
curve of the plot of TNF release vs S:K ratio (Fig. 6 B). Com- 
parison of Fig. 6 A  and B leads to the conclusion that the 
antigen density achieved by infection with rVV was equiva- 
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10 -5.5 M peptide. Thus, we conclude that <1% of the LCL 
displayed antigen at the density equivalent to that achieved 
by exposure to 10-s.5 M  peptide. We cannot, however, ex- 
clude the possibility that an even smaller percentage of the 
LCL displayed antigen at this concentration, or that a lower 
concentration expressed by more cells was sufficient to stimu- 
late CTL. 
Our findings have caused us to reexamine the assumption 
that a higher antigen density is required for T cell activation 
than is needed to trigger effector functions of cytolysis and 
lymphokine release.  The  assumption  is  based  in  part  on 
teleology: It seems to make no sense that the immune system 
should allow activation of effector cells that are unable to 
exert their effector function. Thus, although T  cell activa- 
tion requires a second signal delivered prototypically through 
the B7/CD28 interaction in addition to the signal delivered 
though the antigen-specific TCR, we would still assume that 
the antigen-specific part of signaling for T cell activation would 
require a higher avidity of interaction with target than is re- 
quired for effector functions. This is probably true for the 
initial activation of naive CTL precursors. To activate pri- 
mary in vitro CTL with peptide-loaded antigen presenta- 
tion-deficient T2 or RMAS cells, Melief and co-workers found 
that several logs higher concentration of peptide was required 
than was necessary to sensitize the T2 cells for lysis (19, 19a). 
The phenotype of the cell that activated the naive precursors 
of our CTL in vivo is not known and may differ in antigen 
density from the in vitro LCL; thus, we can draw no conclu- 
sions about the initial activation of our CTL. The evidence 
is less clear about the antigen density requirement for reacti- 
vation of memory CTL and for their continued propagation. 
The most relevant data comes from cross-reactive systems, 
where CTL have been activated in vivo and then restimu- 
lated in vitro with either a cross-reactive alloligand or a so- 
called "antagonist" peptide. Both types ofligands are assumed 
to present a lower affinity interaction to the TCR. The data 
are contradictory. CD4 clones were able to exert effector func- 
tions of lymphokine release and cytolysis but did not proliferate 
in response to an "antagonist" peptide (20). We have observed 
the opposite situation with CD8 + CTL specific for an HIV 
peptide. Here an antagonist peptide could reactivate the CTL 
in vitro but was not able to sensitize targets for lysis (McAdam, 
S., P. Klenerman, L. Tussey, S. Rowland-Jones, D. Lalloo, 
R.  Phillips,  A. Edwards, P.  Giangrande, A. L.  Brown, F. 
Gotch,  et  al.,  manuscript  submitted for publication;  and 
Klenerman, P., U.-C. Meier, R. Phillips, and A. J. McMichael, 
manuscript submitted for publication). A similar situation 
was observed previously for vesicular stomatitis virus-specific 
CTL that could be cross-reactively reactivated by H-2K  bins- 
expressing stimulators but did not lyse H-2KbmS-expressing 
targets (21). Again, the inverse situation (ability of the cross- 
reactive ligand to trigger lysis but not reactivation) has also 
been reported (22).  None of these experimental situations 
corresponds exactly to ours in that, in each case, the presumed 
lower avidity antigenic interaction is achieved by a qualita- 
tively different ligand rather than by an alteration in ligand 
density. Furthermore, the involvement of high MHC den- 
sity dendritic cells in stimulation but not in the lysis assay 
can often not be excluded. Nevertheless, we believe that the 
most likely interpretation of our data is that EBV-specific 
CTL clones were reactivated in vitro from memory CTL by 
an antigenic density on the LCL that was insufficient to trigger 
lysis. 
We regard the major implication of this study as being 
for the investigation of the pathogenesis and control of in- 
fection by EBV. The methods usually used to detect EBV- 
specific CTL do not identify CTL of this phenotype. Acute 
symptomatic EBV infection, both in IM and in the usually 
fatal X-linked lymphoproliferative syndrome (XLP), is charac- 
terized  by  a  marked  expansion  and  activation  of CD8 + 
CTL,  many  of which  lyse  allogeneic  ceils  in  an  EBV- 
independent, dass I-dependent manner (16, 17, 23). Because 
autologous LCL do not competitively inhibit  this lysis, it 
has been assumed that the alloreactive CTL in IM are the 
result of a nonspecific, antigen-independent "bystander" ac- 
tivation of CD8 + T  cells (17). Massive "nonspecific" acti- 
vation of CD8 T cells is considered a hallmark of symptom- 
atic EBV infection, and it has been thought that these may 
play a pathogenic role in XLP, with the concomitant sug- 
gestion that they be controlled by cytotoxic drug therapy (23). 
We report here that EBV-specific CTL frequently fail to lyse 
LCL in vitro and, furthermore, that some of these CTL clones 
exhibit alloreactivity highly reminiscent of that described in 
IM and XLP. We suggest that some or all of the aUoreactive 
and other "nonspecifically activated" CTL seen in symptomatic 
EBV infection may after all be EBV specific but require addi- 
tional antigen to demonstrate their specificity in vitro. 
We do not know whether the in vivo T cells from which 
our  CTL  lines  were derived are  able  to  eliminate EBV- 
transformed B cells in vivo, although we note that our three 
donors are healthy and asymptomatic. The usual procedures 
used to screen for EBV-specific CTL would have precluded 
the identification of CTL displaying this phenotype. We pre- 
dict that CTL of this phenotype could be identified in many 
EBV-seropositive donors. It is possible that screening for these 
CTL will demonstrate that the majority of the expanded ac- 
tivated CD8 + T cell population in acute symptomatic EBV 
infection is in fact specific for EBV antigens. 
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